Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

Presentation AHA 2017

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Presenter: Kenneth W. Mahaffey

November 14, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

Presentation TCT 2017

RESOLVE/SAVORY: Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, Mohamed Abdel-Wahab

November 01, 2017

Presentation TCT 2017

RESOLVE/SAVORY: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Lars Sondergaard

November 01, 2017

Presentation TCT 2017

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Frederick Feit

November 01, 2017

Presentation TCT 2017

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

Presentation TCT 2017

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung

November 01, 2017

Presentation TCT 2017

Is There a Preferred Stent for the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Upendra Kaul

November 01, 2017

Presentation TCT 2017

When Should PCI Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Sripal Bangalore

November 01, 2017

Presentation TCT 2017

When Should CABG Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Jack Boyd

November 01, 2017

Presentation CDM 2017

Can CHD and DM be Prevented? The Answer is on Your Plate

Presenter: Robert A. Vogel

October 05, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

Presentation ESC 2017

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

Presenter: Martin J. Holzmann

August 28, 2017

Presentation EuroPCR 2017

BIO-RESORT Silent Diabetes

Presenter: Clemens von Birgelen

May 19, 2017

Advertisement

Insights from the FOURIER Trial

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

RESOLVE/SAVORY: Critique and Unanswered Questions

RESOLVE/SAVORY: Topline Findings and Practice Implications

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Should Pre-Diabetes Affect Revascularization Decisions?

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Is There a Preferred Stent for the Diabetic Patient?

When Should PCI Be Preferred in the Diabetic Patient?

When Should CABG Be Preferred in the Diabetic Patient?

Can CHD and DM be Prevented? The Answer is on Your Plate

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

BIO-RESORT Silent Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content